Arcadia Investment Advisors’s AbbVie ABBV Stock Holding History

Arcadia Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8	Closed	-$901	–	116
2021 Q2	$901	Buy	+8	New	+$901	﹤0.01%	179

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Arcadia Investment Advisors's ABBV Position: Q3 2021 in Review

Arcadia Investment Advisors sold out of AbbVie (ABBV) in Q3 2021, closing a stake of 8 shares — an estimated $901 sold.

Arcadia Investment Advisors first reported a position in ABBV in Q2 2021 and held it in 1 quarter. The position peaked at $901 in Q2 2021. 2,655 funds tracked by Wall St. Rank hold ABBV as of Q3 2021.

Arcadia Investment Advisors reported no remaining AbbVie position as of Q3 2021 after selling out during the quarter.
Arcadia Investment Advisors sold 8 AbbVie shares in Q3 2021, an estimated $901.
Arcadia Investment Advisors first reported a position in AbbVie in Q2 2021 and held it in 1 quarter.
Arcadia Investment Advisors's AbbVie position peaked at $901 in Q2 2021.
2,655 funds tracked by Wall St. Rank held AbbVie as of Q3 2021.

Based on Arcadia Investment Advisors's 13F filing for Q3 2021, filed 19 Dec 2024.